Glen Oaks, New York 11004


Purpose:

We are conducting a randomized, 24-week, double-blind study, comparing fluoxetine with aripiprazole in 48 patients with attenuated positive symptoms at a level of at least moderate severity.


Study summary:

To Compare Fluoxetine and Aripiprazole on All-cause Discontinuation/Need to Add Another Psychiatric Medication, Symptomatic Improvement, and Adverse Effects


Criteria:

Inclusion Criteria: - consent obtained from patients and their parents (assent for patients under 18); - age 12-25 years (inclusive); - English-speaking; - at least one positive (Scale A) SOPS score of 3-5, i.e., moderate, moderately severe or severe. Exclusion Criteria: - lifetime diagnosis of an Axis I psychotic disorder, including: schizophreniform disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features; - current psychosis (any positive symptom SOPS score of 6, i.e., extreme); - current diagnosis of Major Depressive Disorder, single episode or recurrent, severe without psychotic features; - current stimulant treatment; - history of neurological, neuroendocrine or other medical condition known to affect the brain; - any significant medical condition that contra-indicates treatment with either aripiprazole or fluoxetine; - past or current substance dependence; sunstance abuse within the last 4 weeks; - IQ < 70.


NCT ID:

NCT02357849


Primary Contact:

Principal Investigator
Christoph U Correll, MD
North Shore LIJ

Christoph U Correll, MD
Phone: 718-470-4812
Email: ccorrell@nshs.edu


Backup Contact:

Email: Mbirnbaum@nshs.edu
Michael Birnbaum, MD
Phone: 718-470-8305


Location Contact:

Glen Oaks, New York 11004
United States

Christoph U Correll, MD
Phone: 718-470-4812
Email: ccorrell@nshs.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.